New hope for Alzheimer's psychosis: Long-Term drug trial underway
NCT ID NCT07459660
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug remains safe and tolerable over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ML007C-MA (a combination drug taken twice daily)
What this could lead to
If it works, this could provide a safe, long-term option to ease hallucinations and delusions in people with Alzheimer's disease.
What could go wrong
This is an early-phase, open-label study with no placebo group, so results may not confirm effectiveness. Side effects or lack of benefit could still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Site
RECRUITINGDoral, Florida, 33122, United States
-
Clinical Site
RECRUITINGMiami, Florida, 33155, United States
-
Clinical Site
RECRUITINGMiami, Florida, 33173, United States